Applying Biomarker Information To Support Drug Discovery ... - IIR

More documents

Recommendations

Info

PK/PD Criteria for a Target Molecule IFN 3MIU; tiw PEG 2-fold half-life Serum OAS (% of Baseline) PEG 5-fold half-life PEG 8-fold half-life 0 800 0 800 Time (hours)
PK Profiles of IFN / PEG-IFN in Rats 1000000 10000 1000000 IFN PEG 1 10000 100 100 Serum Conc. (U/ml) 1 0 6 12 18 24 1000000 *PEG-IFN 10000 100 1 0 10 20 30 40 50 1000000 1 0 6 12 18 24 1000000 **PEG-IFN 10000 100 1 0 10 20 30 40 50 1000000 10000 PEGSYS 10000 ***PEG-IFN 100 100 1 0 6 12 18 24 1 0 6 12 18 24 Time (hours)
Page 1 and 2: Applying Biomarker Information To S
Page 3 and 4: Definition: Surrogate Endpoint A bi
Page 5: Develop a New Therapy • Strong Me
Page 9 and 10: Comparison of Pharmacokinetic Profi
Page 11 and 12: Good Correlation between Predicted
Page 13 and 14: Good Correlation between Model Pred
Page 15 and 16: Good Correlation between Model Pred
Page 17 and 18: Findings of PKA Signaling Pathway P
Page 19 and 20: Mechanistic Pharmacology Platform i
Page 21 and 22: Graphic Illustration -- Mechanism o
Page 23 and 24: Model Prediction vs Literature Valu
Page 25 and 26: Effect of PEG-G & Filgrastim on ANC
Page 27 and 28: Mean BFU-E Colony Formation Profile
Page 29: Acknowledgment PEGSYS Project: PKA

Applying Biomarker Information To Support Drug Discovery ... - IIR

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?